merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks, including swelling and bleeding in the brain.</answer>
<question_number>2</question_number>
<answer>It might discourage participation in trials for other Alzheimer's treatments.</answer>
<question_number>3</question_number>
<answer>No correlation between amyloid plaque removal and clinical response in individual subjects.</answer>
<question_number>4</question_number>
<answer>It may lead to concerns about Kisunla's safety.</answer>
<question_number>5</question_number>
<answer>Patients can discontinue treatment after amyloid is cleared.</answer>
<question_number>6</question_number>
<answer>Discourage participation in trials for other treatments.</answer>
<question_number>7</question_number>
<answer>Patients can discontinue treatment after amyloid is cleared, reducing inconvenience.</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius.</answer>
<question_number>10</question_number>
<answer>Intermediate tau levels in trial participants.</answer>